Intralesional TLR4 agonist treatment strengthens the organ defense against colonizing cancer cells in the brain

Raquel Blazquez1,2,14, Han-Ning Chuang2,14, Britta Wenske2, Laura Trigueros1, Darius Wlochowitz2, Renato Liguori1,2,13, Fulvia Ferrazzi4,5, Tommy Regen6,7, Martin A. Proescholdt8, Veit Rohde9, Markus J. Riemschneider10, Christine Stadelmann6, Annalen Bleckmann2,11, Tim Beißbarth3, Denise van Rossum6,12, Uwe K. Hanisch6,15 and Tobias Pukrop1,2,13✉

© The Author(s) 2022

Brain metastasis in breast cancer remains difficult to treat and its incidence is increasing. Therefore, the development of new therapies is of utmost clinical relevance. Recently, toll-like receptor (TLR) 4 was correlated with IL6 expression and poor prognosis in 1 215 breast cancer primaries. In contrast, we demonstrated that TLR4 stimulation reduces microglia-assisted breast cancer cell invasion. However, the expression, prognostic value, or therapeutic potential of TLR signaling in breast cancer brain metastasis have not been investigated. We thus tested the prognostic value of various TLRs in two brain-metastasis gene sets. Furthermore, we investigated different TLR agonists, as well as MyD88 and TRIF-deficient microenvironments in organotypic brain-slice ex vivo cultures and in vivo colonization experiments. These experiments underline the ambiguous roles of TLR4, its adapter MyD88, and the target nitric oxide (NO) during brain colonization. Moreover, analysis of the gene expression datasets of breast cancer brain metastasis patients revealed associations of TLR1 and IL6 with poor overall survival. Finally, our finding that a single LPS application at the onset of colonization shapes the later microglia/macrophage reaction at the macro-metastasis brain-parenchyma interface (MMPI) and reduces metastatic infiltration into the brain parenchyma may prove useful in immunotherapeutic considerations.

Oncogene (2022) 41:5008–5019; https://doi.org/10.1038/s41388-022-02496-3

INTRODUCTION
Brain metastasis (BM) occurs frequently in lung and breast carcinomas [1, 2]. The prevalence is increasing and the efficacy of current therapies remains limited, making BM especially from breast cancer (BCBM) a lethal disease with low survival [3]. Moreover, the brain is inherently the most immune-suppressed organ, such that inflammatory pathways are also less activated in BM. Thus, it is all the more surprising that the toll-like receptor (TLR) signaling pathway is upregulated in brain metastasis of lung-cancer patients [4] and that TLR4 is expressed in microglia during colonization of the brain in a lung-cancer model [5]. However, the role of TLR signaling in BM has not been investigated yet. Nevertheless, in breast primary tumors, TLRs are downregulated in general, but TLR4 expression is associated with poor prognosis [6].

TLRs recognize exogenous pathogen-associated molecular patterns (PAMPs), as well as endogenous ligands, called damage-associated molecular patterns (DAMPs) [7]. In humans, ten TLRs have been identified. TLR1, 2, 4, 5, 6, and 10 are mainly expressed on the plasma membrane, where they recognize bacterial components, such as lipoprotein of Gram-positive bacteria (TLR1, 2, 6, and 10), lipopolysaccharide (LPS) of Gram-negative bacteria (TLR4), and flagellin of bacterial flagella (TLR5). TLR3, 7, 8, and 9 are located intracellularly and are mostly able to detect bacterial or viral nucleic acids, like double-stranded RNA/polyinosinic–polycytidylic acid [poly(I:C)] (TLR3), single-stranded RNA (TLR7), or CpG-containing DNA (CpG-ODN) (TLR9) [8, 9].

In cancer, dying or necrotic tumor cells, damaged extracellular matrix (ECM), or leaky blood vessels release multiple DAMPs, activating their respective receptors. Thus, numerous DAMPs and their combinations are present during cancer progression. For example, TLR4 is activated by ECM components like tenasin C or fibronectin; by plasma membrane components like syndecan or glypican; and intracellular molecules like HMGB1, S100 proteins, or histones, to name just a few. Most importantly, DAMP binding to TLRs often leads to different signaling outcomes than PAMP ligands, both quantitatively and qualitatively [10, 11].

Upon activation, TLRs transmit signals through one or more adapter proteins. All TLRs (except for TLR3) signal through at least MyD88. TLR3 signals through the TRIF pathway; TLR4 signals through both adapters [9]. Additionally, TLR stimulation can lead

1Department of Internal Medicine III, Hematology and Medical Oncology, University Hospital Regensburg, 93053 Regensburg, Germany. 2Department of Hematology and Medical Oncology, University Medical Center Göttingen, 37075 Göttingen, Germany. 3Institute of Medical Bioinformatics, University Medical Center Göttingen, Georg August University, 37075 Göttingen, Germany. 4Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany. 5Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany. 6Institute of Neuropathology, University Medical Center Göttingen, 37075 Göttingen, Germany. 7Department of Neurosurgery, University Hospital Regensburg, 93053 Regensburg, Germany. 8Department of Neurosurgery, University Medical Center Göttingen, 37075 Göttingen, Germany. 9Department of Neurosurgery, University Hospital Regensburg, 93053 Regensburg, Germany. 10Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany. 11Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053 Regensburg, Germany. 12These authors contributed equally: Raquel Blazquez, Han-Ning Chuang. 13Deceased: Uwe K. Hanisch. 14email: tobias.pukrop@ukr.de

Received: 21 February 2022 Revised: 31 August 2022 Accepted: 30 September 2022
Published online: 12 October 2022
to the activation of several pathways in parallel, such as NF-κB, MAPKs, Jun N-terminal kinases, p38, as well as interferon regulatory factors 3, 5, and 7. These potential multiple pathway activations result in a plethora of combinations and outcomes. Moreover, TLR signaling triggers multiple biological actions, including cytokine release, gene induction, and secondary translational modifications. Thus, the outcome of TLR activation is variable and dependent on the ligands, context, and cell type [9, 12].

Despite these uncertainties, several TLR agonists are currently undergoing investigation in clinical trials. For example, the synthetic TLR4 agonist glucopyranosyl lipid A (GLA-SE) is effective against recurrent soft-tissue sarcoma expressing the NY-ESO-1 tumor antigen (CMB305) [13], and intra-tumoral GLA-SE treatment is also under investigation in Merkel cell carcinoma [14].

In previous studies, we demonstrated that stimulating TLR4 with LPS reduces microglia-assisted breast-cancer-cell invasion and that the myeloid compartment of BM can be re-educated towards a more anti-metastatic phenotype in breast-cancer colonization models [15, 16]. Basing on these previous observations, we investigated the prognostic value of various TLRs in BM samples, the potency to push microglia/macrophages into a more anti-metastatic phenotype during CNS colonization, and aimed to rule out potential therapeutic strategies.

RESULTS
Clinical relevance of TLR signaling in BCBM
To investigate the potential clinical relevance of TLR signaling in BCBM, we first checked the expression status of different components of the TLR signaling pathway in two BCBM patient cohorts. Heatmaps confirmed differential TLR activation in BCBM (Fig. 1A). High TLR1 and TLR6 expression significantly correlated with a poorer prognosis in both cohorts (Fig. 1B; Supplementary Figure S1A, and Supplementary Table 1). TLR4 and TLR7 also correlated with a significantly poorer prognosis in the MetaStaSys cohort (Fig. 1B, C and Supplementary Table 1), as previously demonstrated for breast cancer primaries [6]. Interestingly, TLR4 expression was associated with a significantly improved prognosis in the Cosgrove cohort (Fig. 1B, C and Supplementary Table 1). Moreover, expression of the two TLR4 adapters MyD88 and TICAM1 (TRIF) also correlated with opposite outcomes in both cohorts (Supplementary Figure S1A and Supplementary Table 1). Thus, we aimed to elucidate further the role of TLR4 and its downstream adapters MyD88 and TRIF during metastatic brain colonization.

TLR4 mediates metastatic brain infiltration via MyD88
Previously, we reported that stimulation with the TLR4 agonist LPS reduced microglia (MG)-induced invasion of MCF-7 human breast-cancer cells in a modified Boyden chamber assay [15]. Here we focused on the effect of TLR4 signaling during metastatic brain colonization. To this effect, we first tested the infiltration capacity of MCF-7 cells into TLR4-, MyD88-, and TRIF-knockout (KO) brain slices in a 3D organotypic ex vivo co-culture [17]. Unexpectedly, MCF-7 infiltration was significantly reduced in TLR4- and MyD88-deficient brain slices, but remained unchanged in TRIF-deficient brain slices (Fig. 1D). The activation of microglia (MG) and astrocytes (AS) was, however, reduced in both MyD88-/- and TRIF-/- brain slices, and fewer microglial cells moved into the tumor plug compared to the wild-type (WT) co-cultures (Fig. 1E; F and Supplementary Fig. S1B). These results indicate that both TLR4 adapters MyD88 and TRIF are involved in the activation of the MG-AS communication loop during the initial steps of astroglisis. However, only MyD88 supports tumor infiltration into the brain slice. On the one hand, this result is in contradiction with our earlier observation that TLR4 activation reduces MG-induced invasion [15]. On the other hand, it supports our previous finding that colonizing metastatic cells misuse DAMP signaling in the brain parenchyma during metastatic infiltration [18].

TLR4 activation plays an ambivalent role during MG-induced tumor cell infiltration
Intrigued by the potentially contradictory results, we next sought to analyze how TLR stimulation affects metastatic brain infiltration. For this, we treated 3D organotypic ex vivo co-cultures with the TLR4 agonist LPS, the TLR2/1 ligand Pam3CSK4, the TLR3 agonist Poly(A:U), or the TLR-downstream target IFNβ. Interestingly, LPS was able to reduce significantly the infiltration of MCF-7 into WT brain slices (Fig. 2A), while not affecting tumor cell invasion (Fig. 2B). Since MCF-7 infiltration was not affected in TRIF-deficient brain slices (Fig. 1D), we also analyzed the effects of LPS in these co-cultures, but observed no differences (Fig. 2C). This might indicate that TRIF does not contribute to the TLR4-mediated MG-assisted infiltration of tumor cells, but is required for the protective effect of LPS.

We then examined which cells respond most to LPS stimulation. Compared to other cellular components of the organotypic 3D ex vivo co-cultures, the metabolic activity of MG cells was significantly enhanced upon LPS stimulation (Fig. 2D). Thus, our previous [15] and current results indicate that LPS affects mainly MG and subsequent MG-assisted infiltration of MCF-7 into the brain slice. However, the contradictory observations that TLR4 stimulation as well as the absence of the receptor or its adapter MyD88 have the same effect on MCF-7 infiltration required further investigation. One explanation could be that low or high activation levels of TLR4/MyD88 signaling lead to significantly different expression levels of specific TLR4/MyD88 target genes, which in turn would affect the tumor infiltration capacity in opposing ways. Moreover, these dose-dependent effects on metastatic infiltration seem to be exclusive of the TLR4 signaling, since stimulation of other TLRs did not affect the infiltration of the breast cancer cells in our ex vivo model (Fig. 2A).

NO as effector of TLR4 activation
To investigate this hypothesis, we first searched for effector molecules under the control of TLR4, which have significantly higher concentrations upon LPS stimulation in comparison to other TLR ligands. We identified nitric oxide (NO) as a potential candidate. NO production by the inducible NO synthase (iNOS), which is regulated by TLR4 besides other TLRs [19]. Thus, we first examined NO production by MG upon stimulation with the above-mentioned TLR agonists. The release of the short-lived NO was determined as nitrite accumulation. Our results confirmed a robust and high and moderate increase in nitrite after TLR4 or TLR2/1 stimulation, respectively. LPS-induced nitrite production was counteracted by the addition of the NO inhibitor Nω-nitro-L-arginine methyl ester (L-NAME). Moreover, we also identified a reduced nitrite concentration in the untreated control after addition of L-NAME, indicating a baseline production of NO by MG in mono-culture (Fig. 2E).

Next, we challenged the nitrite production by MG in MyD88- and TRIF-deficient situations. In both cases, nitrite release after LPS stimulation was not significantly increased compared to WT MG (Fig. 2F). However, the expression of the inducible NO synthase (iNOS/Nos2) was significantly higher in all cases after LPS stimulation, albeit much more in WT MG (Fig. 2G). These data confirm NO as a downstream target of both TLR4 adapters MyD88 and TRIF.

In addition, we studied the impact of NO in our 3D organotypic brain-slice ex vivo co-culture model. Similar to the diminished MCF-7 infiltration upon LPS stimulation (Fig. 2A), the NO downstream target, 8-bromo-guanosine 3',5'-cyclic monophosphate (8-Br-cGMP), significantly reduced infiltration of MCF-7 into the brain slice (Fig. 2H). Furthermore, NO inhibition with L-NAME also resulted in a significant reduction of MCF-7 infiltration (Fig. 2H),
similarly to the case in the TLR4- and MyD88-deficient micro-environments (Fig. 1D). These results reveal that NO has opposing effects in the brain parenchyma depending on its concentration: baseline NO fostered infiltration, whereas high concentrations prevented it.

TLR4 signaling in syngeneic models

Knowing that LPS stimulation reduces the infiltration of MCF-7 human breast cancer cells in 3D organotypic brain-slice ex vivo co-cultures, we next aimed to investigate the effects of TLR signaling activation in syngeneic models. For this purpose, we employed...
410.4 (Balb/C) and E0771-LG (C57Bl/6) murine breast cancer cell lines. First, we tested the effects of LPS stimulation on tumor growth and invasion. While LPS did not affect tumor growth in any of the cell lines (Fig. 3A), it decreased the invasion of E0771-LG significantly (Fig. 3B). Similar to the results with the human MCF-7, only the stimulation of TLR4 (LPS) and not TLR2/1 (Pam3CSK4) significantly reduced the infiltration of murine 410.4 and E0771-LG cells in the organotypic brain-slice co-cultures (Fig. 3C, D). This is extremely important, taking into account that TLR1 expression is significantly correlated with a poorer prognosis (Fig. 1A–C and Supplementary Fig. 1A). Moreover, stimulation with the NO downstream target, 8-Br-cGMP, significantly reduced infiltration of E0771-LG into the brain slice (Fig. 3D), as previously demonstrated for the human MCF-7 (Fig. 2H). 8-Br-cGMP also diminished infiltration of 410.4, albeit not significantly (Fig. 3C).

TLR4 stimulation changes the histopathological growth pattern (HGP) of brain metastases at the MMPI

Encouraged by these results, we next aimed to investigate the effects of a single local LPS application during breast cancer colonization in an immunocompetent syngeneic model of brain metastasis. Since the MyD88−/− mice had a C57Bl/6 background, we further worked with the C57Bl/6 murine breast cancer cell line E0771-LG for our in vivo experiments. We sought to analyze the effects of a single LPS treatment on overall survival (OS), immune infiltrate, and the histopathological growth pattern (HGP) of brain metastases at the MMPI. We previously demonstrated that the presence of tumor cells is the initiating factor for localized differences in the immune compartment, in particular at the MMPI [20, 21]. Thus, we stereotactically injected the syngeneic E0771-LG cells into the mouse brain parenchyma and performed a single-point application of LPS simultaneously (day 0). The mice were sacrificed upon appearance of neurological symptoms as a sign of macro-metastatic growth (long-term experiment, Fig. 4A). Excitingly, this single LPS application on day 0 led to astonishing changes in the HGP of macro-metastases at the MMPI. Whereas untreated mice demonstrated high degrees of infiltration, mice undergoing LPS application revealed little to no infiltration by the end of the experiment (Fig. 4B). These effects were especially appreciable in WT mice. MyD88-deficient mice treated with LPS also demonstrated decreased infiltration at the MMPI; however, these differences were not significant (Fig. 4B).

Interestingly, the changes in the HGP of brain metastases at the MMPI were accompanied by changes in the OS: WT mice injected with E0771-LG and stimulated with LPS survived 30 days, while the median OS of untreated WT mice was only 18 days. Nevertheless, these differences in OS were not significant (p = 0.258; Fig. 4C). Importantly, LPS stimulation provided a survival advantage to WT mice compared to MyD88-deficient mice (median OS = 30 vs 15 days, respectively; p = 0.006; Fig. 4C). These data again indicate that MyD88 is necessary for the protective effect of LPS.

TLR4 stimulation changes the macrophage/microglia (Mφ/MG) response in brain metastasis

Since the (protective) effects of TLR4 stimulation were lost in a MyD88-deficient environment, we next asked which (immune) cell types were mostly affected in the metastatic bulk tissue. Quantitative PCR (qPCR) analysis of the murine brain metastases revealed no significant differences in tumor load (Ck8), Mφ/MG activation (Cd11b), or AS activation (Gfap) (Fig. 5A and Supplementary Fig. S2A) between WT and MyD88−/− untreated or LPS-treated mice. However, owing to the astonishing changes observed in the HGP, we investigated whether we could detect localized differences in the immune compartment, in particular at the MMPI. Thus, we decided to stain the brain metastases with specific markers for Mφ/MG (Iba1) and AS (Gfap) to reveal potential local differences. Strikingly, the single-point application of LPS at day 0 led to a significantly increased recruitment of Mφ/MG to the MMPI (and not in the metastatic core) only in WT mice (Fig. 5B). Moreover, we did not observe obvious differences in the astrocytes’ compartment (Supplementary Fig. S2B), indicating that the main changes associated with TLR4 stimulation take place at the MMPI in the Mφ/MG compartment.

MyD88-target genes Il6 and Ccl2 contribute to metastatic colonization

Owing to the astonishing consequences of TLR4 stimulation during the long-term experiment, we sought to identify changes occurring at earlier time points potentially responsible for the MyD88-dependent protective effect of LPS. For this, we performed a short-term experiment, in which mice were sacrificed 24 h after tumor cell injection (Fig. 6A). qPCR analysis of mouse brain metastases revealed negligible metastatic burden (Ck8) at this early time point compared to the macro-metastases in the long-term experiment (ACT = 17 vs. 7, respectively) and did not differ among cohorts (Fig. 6B). Owing to the contribution of MyD88 to the protective effect of LPS, we investigated well-described MyD88 target genes, which are relevant during metastasis progression. Interestingly, not all MyD88 target genes were downregulated in MyD88-deficient mice. For example, the expression of the anti-inflammatory cytokine Il10 remained unchanged (Fig. 6B), excluding a random downregulation of MyD88-downstream targets. Due to differences seen in astrogliosis in the 3D organotypic ex vivo co-culture analysis (Fig. 1E, F and Supplementary Fig. 5B), we additionally investigated Csf1r and Gfap as markers for Mφ/MG activation and astrogliosis, respectively. Comparable to the co-culture results, both Csf1r and Gfap were significantly decreased in the MyD88−/− context at this early time point (Fig. 6C). Moreover, unlike Il10, we observed substantial changes in other MyD88-target genes in brain metastases of MyD88-deficient mice. For example, Nos2 and Il1b, known to mediate the communication between Mφ/MG and AS [22], were significantly downregulated in the MyD88-deficient microenvironment, regardless of LPS stimulation (Fig. 6C). This could explain the likewise significantly reduced expression of Mφ/MG and AS marker genes.
Strikingly, *Ccl2* and *Il6*, usually associated with metastasis progression and poor prognosis [23, 24], were expressed greater in MyD88<sup>−/−</sup> mice, reaching significance in the LPS-stimulated cohort (Fig. 6D), offering an explanation for the worse OS (Fig. 4C). To verify this hypothesis, we retrospectively analyzed the prognostic value of these two MyD88-target genes in the two human cohorts (MetastaSys and Cosgrove). While *CCL2* was associated with ambiguous outcomes, *IL6* significantly correlated with a poorer prognosis in both cohorts (Fig. 6E). Therefore, we concentrated on the pharmacological inhibition of *IL6*. However,
Fig. 2  Role of MyD88, TRIF and NO in tumor cell infiltration. A  Organotypic brain-slice ex vivo co-culture with MCF-7 tumor cells and WT brain slices stimulated with LPS (1 µg/ml), Pam3CSK4 (1 µg/ml), recombinant IFNβ (100 ng/ml), or Poly(A:U) (1 µg/ml). Data represent the percentage degree of tumor-cell infiltration into the brain slices after 96 h ($n$ ≥ 12; ***$p$ < 0.001; Mann-Whitney test). B  MCF-7 tumor-cell invasion after PBS (CTRL) or LPS (1 µg/ml) stimulation. Data represent the average tumor cell number migrated per high power field (HPF) after 96 hours ($n$ ≥ 10; mean ± SD; n.s. = not significant; unpaired t-test). C  Organotypic brain-slice ex vivo co-culture with MCF-7 tumor cells and brain slices from TRIF$^{-/-}$ mice after PBS (CTRL) or LPS (1 µg/ml) stimulation. Data represent the percentage degree of tumor-cell infiltration into the brain slices after 96 h ($n$ ≥ 24; Mann-Whitney test). D  Metabolic activity of the indicated cell types after stimulation with PBS (CTRL) or LPS (1 µg/ml) assessed by means of MTT conversion assay ($n$ ≥ 8; mean ± SD; ***$p$ ≤ 0.001; one-way ANOVA followed by Sidak’s multiple comparisons test). E  NO release as a function of nitrite accumulation in supernatants of WT MG after stimulation with L-NAME (1 mM), Pam3CSK4 (10 ng/ml), recombinant IFNβ (10 ng/ml), Poly(A:U) (1 µg/ml), and LPS (100 ng/ml) ($n$ ≥ 6; mean ± SEM; ***$p$ ≤ 0.001; unpaired t-test). F  NO release as a function of nitrite accumulation in supernatants of WT, MyD88$^{-/-}$, and TRIF$^{-/-}$ MG after LPS (100 ng/ml) stimulation. (F1) NO release is indicated as the percentage of nitrite accumulated compared to the control (CTRL; $n$ ≥ 5; mean ± SEM; ****$p$ < 0.0001; one-way ANOVA followed by Sidak’s multiple comparisons). (F2) Representative confocal images depicting iNos induction after LPS stimulation. G  Quantitative RT-PCR analysis of Nos2 expression in wild-type (WT) or MyD88$^{-/-}$ MG after LPS (100 ng/ml) stimulation. Data represent the ΔCt value between the gene of interest (GOI) = Nos2 and two housekeeping (HK) genes ($n$ ≥ 4; mean; ***$p$ < 0.0001; one-way ANOVA followed by Sidak’s multiple comparisons). H  Organotypic brain-slice ex vivo co-culture with MCF-7 tumor cells and stimulated with 8-Br-cGMP (10 µM) or L-NAME (100 µM). Data represent the percentage degree of tumor-cell infiltration into the brain slices after 96 hours ($n$ ≥ 16; **$p$ < 0.01, ***$p$ < 0.001; Mann-Whitney test).

Fig. 3  Effect of TLR activation on tumor cell growth, invasion and infiltration. A  3D tumor cell spheroids (410.4 left, E0771-LG right) formed by the hanging-drop method. (A1) The spheroid area (in mm$^2$) upon treatment with LPS (1 µg/ml) is depicted compared to the control (CTRL; mean ± SD, $n$ ≥ 3; two-way ANOVA followed by Sidak’s multiple comparisons test). (A2) Representative images of spheroid outgrowth after 96 h is illustrated. Scale bars represent 500 µm. B  410.4 (left) or E0771-LG (right) tumor cell invasion after PBS (CTRL) or LPS (1 µg/ml) stimulation. Data represent the average tumor cell number migrated per high power field (HPF) after 96 h ($n$ ≥ 12; mean ± SD; n.s. = not significant, ***$p$ < 0.001; unpaired t-test). Organotypic brain-slice ex vivo co-cultures with 410.4 (C) or E0771-LG (D) tumor cells and stimulated with LPS (1 µg/ml), Pam3CSK4 (1 µg/ml), or 8-Br-cGMP (10 µM). Data represent the percentage degree of tumor-cell infiltration into the brain slices (WT) after 96 hours ($n$ ≥ 14; n.s. = not significant, **$p$ < 0.01; Mann-Whitney test).
Fig. 4 Impact of TLR4 activation via MyD88 on metastatic infiltration and survival. A Scheme depicting the timeline of the long-term in vivo experiment. Median OS of the different groups is indicated. B Characterization of E0771-LG infiltration at the MMPI. (B1) Representative images of histology (HE) and vimentin (VIM) immunohistochemistry (IHC) in coronal brain sections of wild-type (WT) or MyD88 \(^{-/-}\) mice injected with E0771-LG tumor cells and stimulated either with PBS (CTRL) or with LPS (1 \(\mu\)g/ml). Higher magnification images portraying metastatic infiltration at the MMPI are also presented. (B2) Quantification of the degree of tumor cell infiltration at the MMPI is indicated as the percentage of animals with high (++), medium (+), or low (0) metastatic infiltration at the MMPI (\(n \geq 5\); n.s. = not significant; **\(p < 0.01\); Mann-Whitney test). C Kaplan-Meier survival curves of WT (straight line) or MyD88 \(^{-/-}\) (dashed line) mice injected with E0771-LG tumor cells and stimulated either with PBS (black) or with LPS (red) (\(n \geq 6\); **\(p < 0.01\); log-rank test).
IL6 blockade did not significantly impact E0771-LG infiltration into the brain slice (Fig. 6F). This could due to the fact that lymphocytes, which are also activated by IL6, are not present in the organotypic co-culture.

**DISCUSSION**

Our results reveal that TLR1 and TLR6 gene expression, both forming a heterodimer with TLR2, are associated with a worse OS of patients with BCBM. Furthermore, stimulation with Pam3CSK4, a TLR2/1 agonist, does not lead to a more effective anti-tumor activity in organotypic brain-slice ex vivo co-cultures of any breast cancer model. Thus activation of TLR2/1 does not represent a promising therapeutic strategy in BCBM.

However, blocking TLR2 on the receptor level could be a potential target in the CNS. This idea is supported by a glioma model in which TLR2 knockout resulted in reduced glioma growth. In this context, glioma-derived versican was identified as tumor-derived DAMP activating TLR2 on macrophages/microglia [25]. This result confirmed earlier findings, in which versican was also identified as tumor-derived DAMP in a lung-cancer model. In this model, tumor-derived versican was responsible for macrophage recruitment to the metastatic niche. Furthermore, TLR2 knockout reduced the metastatic capacity of this syngeneic lung-cancer model. Moreover, versican-mediated TLR2 activation led, among other effects, to upregulation of IL6. Signaling analysis of the tumor-derived versican-mediated TLR2 signaling identified TLR6 as necessary heterodimer and MyD88 as responsible TLR adapter [26].

While blocking on the TLR2 receptor-level could be a potential target, our results do not support any blockade of its adapter MyD88. Although the absence of MyD88 in the brain parenchyma led to reduced infiltration by tumor cells, it also reduced MG and AS activation in the organotypic brain-slice ex vivo co-cultures and...
Fig. 6  Target genes under the control of TLR4/MyD88. A Scheme depicting the timeline of the short-term in vivo experiments (early colonization). B–D qPCR analysis of the indicated genes in brain metastases of wild-type (WT, dots) or MyD88−/− (squares) mice injected with E0771-LG tumor cells and stimulated either with PBS (CTRL; black) or with LPS (red). Tumors were isolated 24 h after tumor cell inoculation (n ≥ 4; mean; *p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA followed by Sidak’s multiple comparisons). E Kaplan-Meier survival curves of BCBM patients in MetastaSys (left) or Cosgrove (right) cohorts stratified on the basis of CCL2 (top) or IL6 (bottom) expression (P value = log-rank test p-value; HR = hazard ratio). F Organotypic brain-slice ex vivo co-cultures with E0771-LG tumor cells stimulated with isotype control (CTRL) or anti-IL6 (1 µg/ml). Data represent the percentage degree of tumor cell infiltration into the brain slices (WT) after 96 hours (n ≥ 13; Mann-Whitney test). (F2) Representative pictures of the organotypic ex vivo co-cultures with E0771-LG cells (TP tumor plug, BS brain slice). E0771-LG tumor cells are depicted in red and AS (GFAP) are shown in green. Scale bars represent 30 µm.
in the short-term in vivo experiment. Most importantly, MyD88 knockout also revealed no survival benefit in the long-term syngeneic colonization model. Contrary to expectations, Il6, a well-known marker for tumor progression, was expressed greater in the MyD88−/− group in the short-term experiment, in particular after LPS stimulation. Il6 was also associated with poor prognosis in both BCBM data sets. Recently, Il6/Pi3K signaling was described as an activator of disseminated tumor cells (DTCs) [27] and initial perivascular growing cancer cells are sensitive to dual Pi3K/mTOR inhibition during brain colonization [28]. We previously identified Pi3K as master regulator of MG and tumor-associated macrophages (TAMs) during BC metastatic colonization [16]. However, in contrast to the previously described Pi3K-inhibition, anti-il6 treatment did not reduce tumor cell infiltration significantly in our organotypic brain-slice ex vivo experiments. This is in line with the investigations of versican-induced lung-cancer metastasis, in which Il6 knockout caused only small differences in survival [26]. These findings suggest that Pi3K is a more promising target than Il6 or MyD88 in BCBM.

Finally, the results of TLR4 are also ambiguous, like the MyD88 data. This is already evident from the survival analyses of the two BCBM data sets. In these analyses, TLR4 is the only TLR, which has an opposite significant prognostic association with survival. There are already controversial reports of reduced tumor growth and improved survival in TLR4-deficient mice [29–31]. On the contrary, TLR4 activation also leads to the production of IFNβ by tumor cells, contributing to an anti-tumor immune response [32]. These studies indicate that TLR4 signaling and some TLR4 target genes have dual roles during metastatic outgrowth. This data demonstrate that a robust glial defense may only be achieved upon activation of both MyD88 and TRIF. The fact that TLR4 is the only TLR to signal via both adapters makes its stimulation an attractive therapeutic approach. Moreover, LPS led to the most robust NO induction, which is well-known to have a tumoricidal effect at high concentrations [33–35]. On the contrary, low NO concentrations seem to be necessary for metastatic infiltration at the MMPI, which is also supported by previous findings [36].

Taking our in vitro and in vivo results together, we demonstrate here that a robust (local) activation of TLR4 at colonization onset strengthens the local defense during further metastatic outgrowth. This effect is most likely visible at the MMPI, at which a single intralesional LPS treatment at the beginning led to the formation of a compact macrophage wall and a significant reduction in the infiltration of metastatic cells into the adjacent tissue at the end of the experiment. This improved containment of the metastatic bulk required robust local activation of both TLR adapters MyD88 and TRIF. At least at this point, one might remember the earlier clinical studies by William Coley, who also applied a PAMP cocktail comprising bacterial components intravenously to treat cancer [37]. In view of Coley’s early clinical studies and our results, additional LPS treatment on the brain cavity wall after metastasis resection might be a valid study concept to strengthen the local defense system for example in oligo-metastasized disease of BC patients.

**MATERIALS AND METHODS**

**Cell culture and transfection**

MCF-7 cells (DSMZ GmbH, Braunschweig, Germany) were grown on RPMI-1640 medium (PAA Laboratories Inc., Colbe, Germany) supplemented with 10% fetal calf serum (FCS, Invitrogen, Karlsruhe, Germany). E0771-LG and E0771 were kindly provided by Profs. J. Pollard and F. Balkwill (London, UK), respectively, and grown on DMEM 10% FCS. Primary microglia and astrocytes were prepared as previously described [38]. Cells were regularly tested for mycoplasma.

Cells were stably transfected with the plasmid pEGFP-actin (Clontech, Heidelberg, Germany) and mammalian Turbo GFP vector (FPS12, Evrogen Inc., Heidelberg, Germany) using a Nanofectin kit (PAA, Colbe, Germany), or retrovirally transfected with a 2xTumor plasmid (p3x_B1A, mtTomato-2A-puro, Clontech). Selection was achieved using genetin (Roche, Basel, Switzerland) or puromycin (Sigma, Munich, Germany). Cells were sorted regularly (BD FACS Aria II, Heidelberg, Germany).

**Reagents**

Pam3CSK4 and LPS were purchased from Enzo Life Sciences/Alexis (Lörrach, Germany). Poly(A:U) and 8-bromoguanosine-3’,5’-cyclic monophosphate (8-Br-cGMP) were purchased from Sigma. Mouse interferon-β (IFNβ) was sourced from PBL Biomedical Laboratories (Piscataway, NJ, USA). Nitric oxide (NO) synthase inhibitor, Nω-nitro-L-arginine methyl ester (L-NAME) was obtained from Cayman Chemical (Hamburg, Germany). Anti-interleukin-6 (al6) monoclonal antibody (clone MPS-2OF3, cat#BE0046) and the isotype control (rat IgG1, cat#BE0088) were purchased from Biozol (Eching, Germany).

**Animal models**

Animals were bred in the University Medical Center Göttingen (Germany) animal facility and maintained under specific pathogen-free conditions. TLR4 [39], MyD88 [40], and TRIF [41] knockout (KO) mice were kindly provided by Prof. U. K. Hanisch (Göttingen, Germany). All animal work was approved by the Government of Lower Saxony (approval no. 33.4-42502-04-13/266).

Stereotactic intracortical injection was performed as described previously [16]. Briefly, 12-week-old female mice were injected stereotactically with tumor cells (3 µl) and 1 µl PBS or LPS (1 µg/ml) and sacrificed either 24 hours later (short-term experiment) or upon development of neurological symptoms (long-term experiment). Development of neurological symptoms was evaluated in a blind manner. No randomization was used.

**Organotypic brain-slice ex vivo co-culture system**

Organotypic brain-slice ex vivo co-cultures were performed as described previously [15, 17, 42]. The grade of tumor cell infiltration was evaluated in a blind manner.

**Immunofluorescence (IF) staining**

IF staining of astrocytes and microglia in organotypic ex vivo co-cultures was performed as described previously [15, 17, 42]. Image J software (Image J 1.43 f [43]) was used to quantify microglia cells or astrocyte protrusions.

To detect iNOS expression, 2 x 10⁵ microglial cells were seeded on a coverslip and cultured with or without LPS for 24 hours followed by 4% PFA fixation. Polyclonal anti-iNOS antibody (Merck Millipore, Darmstadt, Germany, cat#ABN26) followed by anti-rabbit FITC (Sigma, cat#AP132F) staining was performed at RT for 1 hour each.

**Cell viability assay**

Cells were cultured with PBS or LPS for 24 hours. Metabolic activity was analyzed by measuring 2,3-diphenyl-5-methyltetrazolium chloride (MTT; Sigma) conversion according to standard procedures.

**NO measurements**

NO synthesis was measured in culture supernatants as the end product, i.e., nitrite, using Griess reagent (Merck) as described [19].

**Reverse transcription and quantitative real-time polymerase chain reaction (qPCR)**

RNA isolation, cDNA synthesis and qPCR were performed as described [44]. For primer sequences, refer to Supplementary Table 2.

**3D spheroid cultures (hanging drop assay)**

Drops of 25 µl of medium containing 250 tumor cells were placed on the inside of the lid of a 100-mm plate filled with PBS to create a hydration chamber. Next, the lid was carefully inverted 180° and the hanging drops were incubated for 72 h at 37 °C. Spheroids were transferred into 24-well plates (one spheroid per well) containing cell-culture medium with either PBS or LPS (1 µg/ml) and incubated up to 96 hours at 37 °C. Spheroid outgrowth (mm²) was analyzed with ImageJ.

**Boyd-en Chamber (invasion assay)**

The degree of tumor cell invasion was measured using a Boyd-en chamber assay as described previously [15].
Histology and immunohistochemistry (IHC) of murine brain metastasis

Hematoxylin-eosin (HE) and IHC of murine brain metastasis were performed as described [16]. The degree of tumor cell infiltration at the MMPI was assessed by an experienced observer in a blind manner using the following scoring system: 0 (no infiltration), + (low infiltration), ++ (high infiltration). Microglia and astrocytes were quantitated in triplicate images of selected regions of interest (ROIs) using ImageJ software. Briefly, the RGB image channels were split using color deconvolution. The appropriate channels (brown for IBA1, red for GFAP) were selected and previously established thresholds (defined by pre-analysis) were applied. Finally, the percentage of stained area was measured.

Patient cohorts and RNA sequencing

RNA sequencing (RNA-Seq) data were collected for two BCBM patient cohorts: MetastaSys (n = 40) and Cosgrove et al. [45] (n = 45). For detailed clinical data, see Supplementary Table 3.

MetastaSys cohort: Human CNS material was obtained from the archives of the Institute of Neuropathology (Göttingen) and the Department of Neuropathology (Regensburg) in accordance with the ethics review board clinical data, see Supplementary Table 3.

CODE AVAILABILITY

R code is available upon request.

REFERENCEs

1. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11:352–63.
2. Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol. 2016;127:407–14.
3. Lin X, DeAngelis LM. Treatment of brain metastases. J Clin Oncol. 2015;33:3475–84.
4. Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, et al. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol. Off J Eur Soc Med Oncol/ESMO. 2019;30:1521–30.
5. Schulz M, Michels B, Niesel K, Stein S, Farin H, Rodel F, et al. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progression and therapeutic response. iScience. 2020;23:101178.
6. Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, et al. Expression profile of Toll-like receptors in human breast cancer. Mol Med Rep. 2020;21:786–94.
7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–76.
8. Drexler SK, Foxwell BM. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol. 2010;42:506–18.
9. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006;117:979–87.
10. Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory dis- eases. Immune Netw. 2018;18:e227.
11. Jang GY, Lee JW, Kim YS, Lee SE, Han HD, Hong KJ, et al. Interactions between tumor-derived proteins and Toll-like receptors. Exp Mol Med. 2020;52:1926–35.
12. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition recep- tors and their cross talk. Annu Rev Biochem. 2007;76:447–80.
13. Somaiah N, Chawla SP, Block MS, Morris JC, Do KT, Kim JW, et al. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+- recurrent soft tissue sarcomas (STS). J Clin Oncol. 2017;35:11006.
14. Bhatia S, Miller NJ, Lu H, Longino NV, Ibrani D, Shinohara MM, et al. Intratumoral G100, a TLRA agonist, induces antitumor immune responses and tumor regres- sion in patients with Merkel cell carcinoma. Clin Cancer Res. 2019;25:1185–95.
15. Pukrop T, Dehghani F, Chuang HN, Lohaus R, Bayanga K, Heermann S, et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt- dependent way. GLIA 2018;66:2438–55.
16. Blazquez R, Wlochowitz D, Wolf A, Seitz S, Wachtler A, Perea-Bel J, et al. P13K: A master regulator of brain metastasis-promoting/macrophages. Microglia. Glia 2018;66:2438–55.
17. Chuang HN, Lohaus R, Hanisch UK, Binder C, Dehghani F, Pukrop T. Coculture system with an organotypic brain slice and 3D spheroid of carcinoma cells. J Vis Exp. 2013;80:50881.
18. Chuang HN, van Rossum D, Sieger D, Siam L, Klemm F, Bleckmann A, et al. Carcinoma cells misuse the host tissue damage response to invade the brain. Glia 2013;61:1331–46.
19. Tumurkhuu G, Koide N, Dagvadorj J, Noman AS, Khuda II, Naiki Y, et al. PI3K: A master regulator of brain metastasis-promoting/macrophages. Microglia. Glia 2018;66:2438–55.
20. Jang GY, Lee JW, Kim YS, Lee SE, Han HD, Hong KJ, et al. Interactions between tumor-derived proteins and Toll-like receptors. Exp Mol Med. 2020;52:1926–35.
21. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition recep- tors and their cross talk. Annu Rev Biochem. 2007;76:447–80.
22. Sanmarco LM, Polonio CM, Wheeler MA, Quintana FJ. Functional immune cell- astrocyte interactions. J Exp Med. 2021;218:e20202715.
23. Hajal C, Shin Y, Li L, Serrano JC, Jacks T, Kamm RD. The CCL2-CCR2 astrocyte- cancer cell axis in tumor extravasation at the brain. Sci Adv. 2021;7:eabg8139.
24. Schulz M, Michels B, Niesel K, Stein S, Farin H, Rodel F, et al. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progression and therapeutic response. iScience. 2020;23:101178.
25. Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, et al. Expression profile of Toll-like receptors in human breast cancer. Mol Med Rep. 2020;21:786–94.
26. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–76.
27. Drexler SK, Foxwell BM. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol. 2010;42:506–18.
28. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol. 2006;117:979–87.
29. Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory dis- eases. Immune Netw. 2018;18:e227.
30. Jang GY, Lee JW, Kim YS, Lee SE, Han HD, Hong KJ, et al. Interactions between tumor-derived proteins and Toll-like receptors. Exp Mol Med. 2020;52:1926–35.
31. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition recep- tors and their cross talk. Annu Rev Biochem. 2007;76:447–80.
32. Somaiah N, Chawla SP, Block MS, Morris JC, Do KT, Kim JW, et al. Immune response, safety, and survival impact from CMB305 in NY-ESO-1+- recurrent soft tissue sarcomas (STS). J Clin Oncol. 2017;35:11006.
33. Bhatia S, Miller NJ, Lu H, Longino NV, Ibrani D, Shinohara MM, et al. Intratumoral G100, a TLRA agonist, induces antitumor immune responses and tumor regres- sion in patients with Merkel cell carcinoma. Clin Cancer Res. 2019;25:1185–95.
34. Pukrop T, Dehghani F, Chuang HN, Lohaus R, Bayanga K, Heermann S, et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt- dependent way. GLIA 2018;66:2438–55.
35. Blazquez R, Wlochowitz D, Wolf A, Seitz S, Wachtler A, Perea-Bel J, et al. P13K: A master regulator of brain metastasis-promoting/macrophages. Microglia. Glia 2018;66:2438–55.
36. Chuang HN, Lohaus R, Hanisch UK, Binder C, Dehghani F, Pukrop T. Coculture system with an organotypic brain slice and 3D spheroid of carcinoma cells. J Vis Exp. 2013;80:50881.
37. Chuang HN, van Rossum D, Sieger D, Siam L, Klemm F, Bleckmann A, et al. Carcinoma cells misuse the host tissue damage response to invade the brain. Glia 2013;61:1331–46.
38. Tumurkhuu G, Koide N, Dagvadorj J, Noman AS, Khuda II, Naiki Y, et al. PI3K: A master regulator of brain metastasis-promoting/macrophages. Microglia. Glia 2018;66:2438–55.
39. Jang GY, Lee JW, Kim YS, Lee SE, Han HD, Hong KJ, et al. Interactions between tumor-derived proteins and Toll-like receptors. Exp Mol Med. 2020;52:1926–35.
40. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition recep- tors and their cross talk. Annu Rev Biochem. 2007;76:447–80.
transflecting the cells and Dr. Ulrike Friedrich (Institute of Human Genetics, University of Regensburg, Germany) for her support with the FV3000 confocal microscope.

**AUTHOR CONTRIBUTIONS**

RB, HNC, UKH, and TP conceived and designed the work. RB, HNC, BW, LT, DW, RL, FF and TR acquired and analyzed the data. TR, MAP, VR, CS, AB, TB, DvR, and UKH assisted with interpretation of the results. RB and TP drafted the manuscript. All authors revised the manuscript, approved the final version, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**FUNDING**

This work was supported by the Deutsche Forschungsgemeinschaft projects DFG PU 355/4-1, FOR2127 (PU 355/5-1) and SFB/TRR 305/1 (B03 and Z01); and the German Federal Ministry of Education and Research (BMBF) projects eBio MetaSys on the platform Medical Systems (0316173C) and eMed MyPathSem (031L0024). The FV3000 confocal microscope was also funded by a grant (INST 89/506-1 FUGG, 91b GG) from the DFG. Open Access funding enabled and organized by Projekt DEAL.

**COMPETING INTERESTS**

The authors declare no competing interests.

**ADDITIONAL INFORMATION**

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41388-022-02496-3.

Correspondence and requests for materials should be addressed to Tobias Pukrop.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**ACKNOWLEDGEMENTS**

The authors thank Elena Vollmer and Gunnar Müller (Dept. of Medical Oncology, University Hospital Regensburg, Germany) for their excellent technical assistance and Dr. Laila Sam (Dept. of Neurosurgery, University Medical Center Göttingen, Germany), Meike Schaffrinski, and Daniela Egert (Dept. of Medical Oncology, University Medical Center Göttingen, Germany) for their contribution in collecting and processing human samples. The authors also thank Dr. Marc Stemmler (Dept. of Experimental Medicine I, Nikolaus-Fiebig-Center for Molecular Medicine, University Erlangen-Nuremberg, Germany) for providing the tdTomato plasmid, Dr. Martin Stenzel (Institute of Clinical Immunology, University Erlangen-Nuremberg, Germany) for

---

30. Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010;52:1322–33.
31. Lee CH, Wu CL, Shiu AL. Toll-like receptor 4 signaling promotes tumor growth. J Immunother. 2010;33:73–82.
32. Nunez NG, Andreani V, Crespo DA, Niocera DL, Moron G, et al. IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012;72:592–603.
33. Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, et al. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. The J Exp Med. 2010;207:2455–67.
34. Lechner M, Link P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol. 2005;15:277–89.
35. Cheng H, Wang L, Mollica M, Re AT, Wu S, Zuo L. Nitric oxide in cancer metastasis. Cancer Lett. 2014;353:1–7.
36. Heinecke JL, Ridnour LA, Cheng HY, Switzer CH, Lizardo MM, Khanna C, et al. Tumor microenvironment-based feed-forward regulation of NO52 in breast cancer progression. Proc Natl Acad Sci USA. 2014;111:6323–8.
37. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991:2623–11.
38. Regen T, van Rossum D, Scheffel J, Kasitriti ME, Revelo NH, Prinz M, et al. CD14 and TRIF govern distinct responsiveness and responses in mouse microglial TLR4 challenges by structural variants of LPS. Brain Behav Immun. 2011;25:957–70.
39. Pfltorak A, Smirnova I, He X, Liu MY, Van Huffer C, McNally O, et al. Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis. 1998;24:340–55.
40. Adachi O, Kawat T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998;9:143–50.
41. Hoebee K, Janssen EM, Kim SO, Alespoulu L, Flavell RA, Han J, et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol. 2003;4:1223–9.
42. Blazquez R, Pukrop T. 3D coculture model of the brain parenchyma-metastasis interface of brain metastasis. Methods Mol Biol. 2017;1612:213–22.
43. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5.
44. Klemm F, Bleckmann A, Back T, Hussain SP, He P, Maciag AE, et al. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. The J Exp Med. 2010;207:2455–67.
45. Lechner M, Link P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol. 2005;15:277–89.